Home > News > Update

Fully Optimised Aptamers

Introducing OptimersTM
3rd October 2018
 
Proprietary process with validated improvement in delivery and performance

OptimersTM in 12 weeks
Aptamer Group is pleased to announce availability of  OptimersTM – the new standard for our custom development services.

Aptamer Group is dedicated to continually improve its service offerings to identify the best reagent(s) from within our vast aptamer libraries in the […]

Aptamer Group Secures $2.2m Series A Investment

Arron Tolley, CEO – I’m delighted to announce that Aptamer Group Ltd, has recently closed its Series A investment round; attracting international interest and securing $2.2m of funding from overseas investors, to support its pioneering aptamer development pipeline.

Aptamer technology is rapidly evolving and will continue to have a significant impact on the life sciences market […]

Biosensors developed using aptamers distinguish between closely related small molecules

4th May 2018

Development of biosensors for the detection of small molecules is notoriously difficult due to the lack of suitable antibodies and the relatively small signals, which result upon small molecule binding to them. At Aptamer Group we select aptamers that bind to small molecules with high specificity and undergo a substantial conformational change that gives […]

Aptamer Group Update: Quarter 3

Message from the CEO
I am pleased to report that the trends mentioned in the last Newsletter continue to improve. We can now boast successful delivery of aptamers to a range of small and large molecule targets for customers in academia, biotech and big Pharma. We are also moving towards integration of aptamers into devices and […]

Spotlight: Selection Technician, Mateja Vidic

19th September, 2017
An insight into working at Aptamer Group
Mateja joined Aptamer Group in August as a Selection Technician. Now she has had the chance to  settle in and become established in her role, we took the opportunity to catch up with her.
Can you tell us a bit about your Ph.D.?
I have just finished the research […]

  • Monoclonal data for aptamer selection in complex media

Aptamer Selection in Complex Media

25th August, 2017
Starting with the end in mind
The use of aptamers in point of care diagnostic devices, for monitoring drug dose levels or for use as therapeutics, requires functionality across a wide variety of conditions.

Aptamer selection starts in conditions optimised to promote aptamer/target interaction to identify the best target-binders. Subsequently, by introducing different pressures, we […]

  • Comparing healthy to disease state cells using aptamers

Aptamer Application: Biomarker Discovery

22nd August, 2017.
Biomarker Discovery

A biomarker is a measurable indicator showing the presence or severity of a disease state. Using biomarkers to differentiate between healthy and diseased cells can enable the development of specific diagnostics, research tools and targeted therapeutics.

Biomarker Discovery using Aptamers

Traditional biomarker discovery is a long process and relies on multiple comparisons using various […]

  • Aptamer, Flow Cytometry, Data, Stain, Antibody Alternative

Aptamer Application: Flow Cytometry

1st August, 2017.
Flow Cytometry
Flow Cytometry is a technique used to identify biomarkers on cell surfaces and intracellular molecules. Most flow cytometers use fluorescently labelled antibodies to differentiate between cells expressing different markers.

Initially the cell sample is suspended, stained with a fluorescent label and washed to remove any non-specific binding. The suspension is introduced into the […]

Aptamer Group Update: Quarter 2

19th June 2017
 

Despite the current volatile environment for small businesses, Aptamer Group continues to grow and prosper. We are regularly delivering aptamers selected against small molecule and protein targets to our customers for a range of applications. The Aptamer Group is at an important stage of its evolution and in addition to collaborating with global […]